T Jordan Walter1, Montserrat Navarro2,3, Todd E Thiele2,3, Cort Pedersen4, Alexey Kampov-Polevoy4, J C Garbutt3,4. 1. Pharmacology Department, University of North Carolina, 120 Mason Farm Road, 4010 Genetic Medicine Building, Campus Box 7365, Chapel Hill, NC 27514, USA. 2. Psychology & Neuroscience Department, University of North Carolina, 235 E Cameron Ave, Chapel Hill, NC 27599, USA. 3. Bowles Center for Alcohol Studies, 104 Manning Drive, CB #7178, Chapel Hill, NC 27599, USA. 4. Psychiatry Department, University of North Carolina, 101 Manning Drive, Ste 7160, Chapel Hill, NC 27514, USA.
Abstract
AIMS: The combination of bupropion and naltrexone has shown efficacy in reducing binge drinking in animal models. This study assessed the tolerability and potential utility of combined naltrexone and bupropion in reducing binge drinking in human subjects. METHODS: This preliminary study employed an open-label, single-arm, 12-week, prospective design. Twelve men and women who exhibited a minimum of five (men) or three (women) binge drinking episodes per month over the past 3 months were recruited. All subjects received both bupropion-extended release 300 mg/day and naltrexone 50 mg/day and were monitored throughout the 3-month treatment period. Binge drinking was assessed using the timeline follow-back method. RESULTS: Treatment with combined naltrexone and bupropion reduced the average number of drinks per binge drinking day from 7.8 drinks to 6.4 drinks and reduced the average percentage of binge drinking days per month from 19% (5.7 days/month) to 5% (1.5 days/month). Naltrexone and bupropion were generally well tolerated, with insomnia, headache and nausea/diarrhea being the most common side effects. Six subjects elected to stay on medication after the trial. CONCLUSIONS: This study suggests that combined naltrexone and bupropion therapy should be further investigated for tolerability and efficacy in reducing binge drinking in humans.
AIMS: The combination of bupropion and naltrexone has shown efficacy in reducing binge drinking in animal models. This study assessed the tolerability and potential utility of combined naltrexone and bupropion in reducing binge drinking in human subjects. METHODS: This preliminary study employed an open-label, single-arm, 12-week, prospective design. Twelve men and women who exhibited a minimum of five (men) or three (women) binge drinking episodes per month over the past 3 months were recruited. All subjects received both bupropion-extended release 300 mg/day and naltrexone 50 mg/day and were monitored throughout the 3-month treatment period. Binge drinking was assessed using the timeline follow-back method. RESULTS: Treatment with combined naltrexone and bupropion reduced the average number of drinks per binge drinking day from 7.8 drinks to 6.4 drinks and reduced the average percentage of binge drinking days per month from 19% (5.7 days/month) to 5% (1.5 days/month). Naltrexone and bupropion were generally well tolerated, with insomnia, headache and nausea/diarrhea being the most common side effects. Six subjects elected to stay on medication after the trial. CONCLUSIONS: This study suggests that combined naltrexone and bupropion therapy should be further investigated for tolerability and efficacy in reducing binge drinking in humans.
Authors: Robert F Leeman; Rebekka S Palmer; William R Corbin; Denise M Romano; Boris Meandzija; Stephanie S O'Malley Journal: Addict Behav Date: 2008-04-13 Impact factor: 3.913
Authors: Frank L Greenway; Ken Fujioka; Raymond A Plodkowski; Sunder Mudaliar; Maria Guttadauria; Janelle Erickson; Dennis D Kim; Eduardo Dunayevich Journal: Lancet Date: 2010-07-29 Impact factor: 79.321
Authors: Amanda Elton; Samantha Dove; Cory N Spencer; Donita L Robinson; Charlotte A Boettiger Journal: Alcohol Clin Exp Res Date: 2019-04-08 Impact factor: 3.455
Authors: Montserrat Navarro; Kendall L Luhn; Alexey B Kampov-Polevoy; James C Garbutt; Todd E Thiele Journal: Alcohol Clin Exp Res Date: 2019-03-19 Impact factor: 3.455
Authors: Roger D Weiss; Stephanie S O'malley; James D Hosking; Joseph S Locastro; Robert Swift Journal: J Stud Alcohol Drugs Date: 2008-11 Impact factor: 2.582
Authors: Justine A Grosso; Elizabeth E Epstein; Barbara S McCrady; Ayorkor Gaba; Sharon Cook; Lindsey M Backer-Fulghum; Fiona S Graff Journal: Addict Behav Date: 2013-02-19 Impact factor: 3.913
Authors: Marcelo F Lopez; Sarah E Reasons; Benjamin A Carper; Tracy L Nolen; Rick L Williams; Howard C Becker Journal: Alcohol Date: 2020-07-24 Impact factor: 2.405
Authors: Nathan W Burnham; Corryn N Chaimowitz; Cortland C Vis; Ana Paula Segantine Dornellas; Montserrat Navarro; Todd E Thiele Journal: Neuropharmacology Date: 2021-07-08 Impact factor: 5.273
Authors: José Manuel Lerma-Cabrera; Francisca Carvajal; James C Garbutt; Montserrat Navarro; Todd E Thiele Journal: Brain Res Date: 2019-12-28 Impact factor: 3.252